MT Newswires
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
📊
AI Sentiment
Positive
6/10
- Home
- SNY
SNY
Sanofi ADS
as of 12-05-2025 3:57pm EST
$49.49
+$0.57
+1.17%
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Chart Type:
Time Range:
| Founded: | 1994 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 119.4B | IPO Year: | N/A |
| Target Price: | $61.50 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 8.67 | EPS Growth: | 105.93 |
| 52 Week Low/High: | $44.62 - $60.12 | Next Earning Date: | 10-24-2025 |
| Revenue: | $53,890,648,839 | Revenue Growth: | -5.19% |
| Revenue Growth (this year): | 2.37% | Revenue Growth (next year): | 6.51% |
AI-Powered SNY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 67.76%
67.76%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Sanofi ADS News
SNY Breaking Stock News: Dive into SNY Ticker-Specific Updates for Smart Investing
PR Newswire
Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 2025 ASH Annual Meeting
📈
AI Sentiment
Highly Positive
8/10
Zacks
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi
📊
AI Sentiment
Positive
6/10
Simply Wall St.
Is Sanofi Now an Opportunity After Recent R and D and Portfolio Reshaping Moves?
📊
AI Sentiment
Positive
7/10
MT Newswires
Sanofi Completes Vicebio Acquisition to Add Respiratory Vaccine Candidate
📊
AI Sentiment
Positive
6/10
GlobeNewswire
Press Release: Sanofi completes acquisition of Vicebio
📈
AI Sentiment
Highly Positive
8/10
Business Wire
LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes
📈
AI Sentiment
Highly Positive
9/10
Zacks Small Cap Research
ARWR: Multiple Data Readouts Ahead in 2026…
📈
AI Sentiment
Highly Positive
8/10
Compare SNY vs Leading Stocks
See how SNY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SNY Sanofi ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.